Blood pressure drugs can prevent heart attacks and strokes, but their protection may fade when too many doses are missed. New research presented at ESC Congress 2026 provides some of the clearest evidence yet that consistently taking antihypertensive medication is essential to receiving its cardiovascular benefits. The analysis used randomized trial data to separate the [...]Pulmonary arterial hypertension (PAH) is being redefined by molecular biology. Once viewed mainly as a disorder of excessive blood-vessel constriction, the disease is now understood as a progressive process involving vascular remodeling, immune activation, metabolic disruption, and inherited susceptibility. A review published online on June 17, 2026, in the Chinese Medical Journal describes how these interacting mechanisms are reshaping PAH research and opening the door to treatments designed not only to relieve symptoms, but also to alter the disease itself.
PAH is a rare and potentially fatal condition in which the small arteries carrying blood through the lungs become narrowed and structurally damaged. As resistance within the pulmonary circulation rises, the right side of the heart must pump harder to maintain blood flow. Over time, the right ventricle can enlarge, weaken, and fail. Current therapies have improved survival, but many patients continue to experience progressive disease, limited exercise capacity, and an uncertain long-term outlook. The new review was conducted by Dr. Taeil Yang of Gil Medical Center at Gachon University College of Medicine and Professor Wook-Jin Chung of the Gachon Cardiovascular Research Institute in the Republic of Korea.
The authors explain that PAH develops through a complex interaction among several types of cells in the pulmonary circulation. Endothelial cells, which form the inner lining of blood vessels, normally regulate vessel diameter, blood flow, clotting, and repair. In PAH, these cells become dysfunctional and can produce excessive vasoconstrictors while reducing protective signals such as nitric oxide and prostacyclin. Endothelial injury also promotes the recruitment of inflammatory cells and stimulates neighboring smooth-muscle cells and fibroblasts to multiply. The resulting changes thicken the vessel wall and progressively reduce the space available for blood flow.
Inflammation is another central feature of this transformation. T cells, B cells, macrophages, and other immune cells can accumulate around pulmonary arteries, releasing cytokines and growth factors that sustain vascular injury. Rather than being a temporary response to damage, this immune activity may become chronic, reinforcing the abnormal behavior of vascular cells. The review emphasizes that immune signaling is closely connected to endothelial dysfunction and tissue remodeling, suggesting that PAH cannot be fully understood by studying blood-vessel tone alone.
The metabolism of pulmonary vascular cells also changes as the disease advances. Under normal conditions, mitochondria generate much of the energy required for cellular function through oxidative phosphorylation. In PAH, endothelial and smooth-muscle cells may shift toward glycolysis, a pattern resembling the “Warburg effect” observed in cancer. This metabolic reprogramming allows cells to generate energy rapidly while supporting biosynthesis and proliferation. It can also increase resistance to programmed cell death, enabling abnormal cells to persist within the vessel wall. These changes help explain why pulmonary arteries can continue remodeling even when vasoconstriction is medically controlled.
Genetic research has provided some of the strongest evidence that PAH is driven by specific biological pathways. Variants in BMPR2, the gene most commonly associated with heritable PAH, can impair signaling involved in vascular growth, repair, and cell survival. Other genes linked to PAH include SOX17, TBX4, and KCNK3. Several of these genes influence the bone morphogenetic protein, or BMP, pathway and its relationship with transforming growth factor beta, known as TGF-β. When this signaling network is disrupted, the balance between controlled growth and abnormal proliferation can shift, increasing susceptibility to pulmonary vascular disease. Genetic risk, however, is not destiny: environmental exposures, inflammation, infections, hormonal influences, and other biological triggers may determine whether disease develops and how rapidly it progresses.
These discoveries are already influencing treatment strategies. Traditional PAH medicines primarily target pathways that regulate vascular constriction, including endothelin, nitric oxide, and prostacyclin signaling. Newer approaches aim deeper at the mechanisms driving vascular remodeling. Sotatercept has attracted particular attention because it acts on signaling within the BMP/TGF-β superfamily and is designed to restore a healthier balance between growth-promoting and growth-inhibiting signals. By targeting the biology of vessel-wall remodeling rather than simply dilating arteries, the therapy represents a shift toward disease modification. Researchers are also studying seralutinib, which targets growth-factor and platelet-derived growth-factor signaling, as well as immune-directed treatments such as tocilizumab and rituximab. Metabolism-focused therapies remain another active area of investigation.
The review also highlights the growing importance of multi-omics research. Genomics can reveal inherited variants, while transcriptomics shows which genes are active in diseased tissue. Proteomics measures changes in proteins and signaling molecules, and metabolomics captures the chemical products of altered cellular pathways. Combining these layers may reveal why patients with apparently similar clinical diagnoses can have very different disease trajectories or responses to therapy. Such information could eventually help physicians classify patients according to molecular subtypes, identify biomarkers before irreversible vascular damage occurs, and select treatments according to the dominant mechanism in each individual.
Professor Chung argues that the most promising future for PAH depends on connecting laboratory discoveries with carefully designed translational studies and clinical trials. That challenge is substantial because the disease involves multiple interacting cell types and pathways, and because tissue samples from the pulmonary circulation are difficult to obtain. Nevertheless, the expanding molecular framework is changing the goals of treatment. Instead of focusing exclusively on lowering pulmonary artery pressure, researchers are seeking ways to repair endothelial dysfunction, restrain immune activity, normalize cellular metabolism, and reverse pathological remodeling. The field is moving toward precision medicine in which genetic and molecular information may guide therapy, offering patients the possibility of longer-lasting control and, ultimately, recovery of healthier pulmonary vascular function.
Subject of Research: Pulmonary arterial hypertension and its molecular mechanisms and emerging treatments
Article Title: Pulmonary arterial hypertension from a translational perspective: Bridging pathophysiology and treatment
News Publication Date: 17-Jun-2026
Web References: https://doi.org/10.1097/CM9.0000000000004137
References: Chinese Medical Journal, DOI: 10.1097/CM9.0000000000004137
Image Credits: Chinese Medical Journal
Keywords: Pulmonary arterial hypertension; PAH; BMPR2; SOX17; TBX4; KCNK3; BMP signaling; TGF-β; vascular remodeling; endothelial dysfunction; inflammation; metabolic reprogramming; sotatercept; seralutinib; precision medicine
In a perspective paper published in The American Journal of Clinical Nutrition, a team of researchers and health experts calls for a ‘paradigm shift’ in how public health agencies address hypertension.
The post Scientists Propose New Strategy in Fight against High Blood Pressure appeared first on Sci.News: Breaking Science News.
Not all sources of dietary sugar appear to affect cardiovascular health in the same way, and one common drink may be less harmless than many assume. A child’s everyday drink choices may leave a cardiovascular imprint that lasts for decades. A long-term study of more than 25,000 people found that frequent consumption of sugar-sweetened beverages [...]
In a groundbreaking study that promises new horizons in the treatment of hypertension-associated cognitive decline, researchers have uncovered the potential of hydrogen sulfide (H₂S) as a therapeutic agent to alleviate spatial learning deficits. This novel work, spearheaded by Kumar, Mishra, and Goswami, delves into the intricate molecular pathways by which H₂S mediates neuroprotection in the context of angiotensin II-induced hypertension, revealing the suppression of endothelial NOX2 and subsequent neuroinflammatory cascades as a key mechanism. These findings not only expand our understanding of the pathophysiological link between hypertension and cognitive impairment but also highlight the therapeutic promise of gaseous signaling molecules in neurovascular health.
Hypertension, a pervasive cardiovascular disorder, has long been implicated in cognitive decline and an increased risk of neurodegenerative diseases. The relationship between elevated blood pressure and impaired spatial learning is complex, involving multifactorial processes such as oxidative stress, endothelial dysfunction, and neuroinflammation. This study addresses the critical gap in understanding how these pathological mechanisms interplay and how specifically targeting them might prevent or reverse cognitive deficits commonly observed in hypertensive patients.
A central player in this pathology is the NADPH oxidase 2 (NOX2), an enzyme prominently expressed in the endothelium and a major producer of reactive oxygen species (ROS). Overactivation of NOX2 leads to excessive oxidative stress, which in turn triggers inflammatory pathways damaging neuronal networks essential for spatial learning and memory. The research identifies NOX2 not merely as a bystander but as a pivotal driver of the neuroinflammatory processes exacerbated by angiotensin II, a peptide hormone central to blood pressure regulation.
The role of hydrogen sulfide in cellular signaling has emerged as a vibrant area of research, particularly its cytoprotective effects in the cardiovascular system. This gasotransmitter is synthesized endogenously and exerts diverse biological functions, including vasodilation, anti-apoptotic actions, and antioxidant effects. Intriguingly, H₂S is shown to modulate the activity of endothelial cells, suggesting a potential intersection between vascular health and cognitive function. The study meticulously explores how administrating exogenous H₂S can modulate endothelial responses in hypertensive models.
Utilizing advanced in vivo models of angiotensin II-induced hypertension, the researchers employed comprehensive behavioral assays to evaluate spatial learning and memory deficits. These studies revealed pronounced impairments consistent with neuroanatomical and functional alterations within the hippocampus, a brain region integral to spatial navigation. The administration of hydrogen sulfide donors elicited a marked reduction in cognitive deficits, underscoring the functional significance of H₂S in this setting.
At the molecular level, the investigation demonstrated that hydrogen sulfide suppresses NOX2 expression and activity in endothelial cells exposed to hypertensive stimuli. This effect culminates in reduced oxidative stress and diminished activation of downstream pro-inflammatory mediators such as cytokines and microglial markers. The attenuation of these pathways underscores the multifaceted influence of H₂S in preserving the integrity of the neurovascular unit under conditions of elevated blood pressure.
Moreover, this research sheds light on the intricate interaction between endothelial dysfunction and neuroinflammation, which has emerged as a critical nexus in the pathogenesis of cognitive decline. The findings suggest that endothelial-derived oxidative stress and inflammation contribute to microglial activation and neuronal damage, processes that H₂S effectively counters. This adds a new layer to our conceptual framework of how vascular health dictates neural outcomes.
From a translational perspective, the study offers compelling evidence supporting hydrogen sulfide donors as viable therapeutic agents. The modulation of NOX2 and inflammatory pathways by H₂S paves the way for pharmacological strategies aimed at mitigating hypertension-induced neural deficits without directly targeting blood pressure itself. Such approaches could complement existing antihypertensive therapies, broadening the arsenal against cognitive impairment in hypertensive populations.
Importantly, the safety profile and physiological relevance of hydrogen sulfide administration were addressed, with the researchers noting minimal adverse effects in the animal models. This aspect is crucial given the dual nature of H₂S, which at elevated concentrations can be toxic. The study’s careful titration of dose and delivery methods serves as a valuable blueprint for future clinical investigations.
Another notable contribution of the study is its use of molecular imaging and histological techniques that corroborate the behavioral findings. These methodologies revealed decreased markers of oxidative damage and neuroinflammation in treated samples, providing robust evidence that H₂S exerts its effects through tangible cellular and tissue-level changes. Such multimodal validation strengthens the case for H₂S’s integrative role in neurovascular protection.
The work also prompts intriguing questions about the broader implications of gasotransmitters in neurodegeneration. Given the overlapping mechanisms of vascular and neurodegenerative diseases, the therapeutic modulation of gas signaling pathways may represent a paradigm shift in managing multifactorial brain disorders. This article can stimulate further research into the cross-talk between vascular function and cognitive health, championing hydrogen sulfide and related molecules as key modulators.
Furthermore, the research adds to the growing body of literature underscoring the critical importance of the endothelial interface in neural function. By targeting endothelial NOX2, hydrogen sulfide indirectly protects neural cells from oxidative and inflammatory insults, delineating an elegant mechanism wherein vascular and neural health are inextricably linked. This insight encourages a more integrated approach to cardiovascular and cognitive care.
As hypertension continues to affect millions worldwide and remains a predominant risk factor for dementia and stroke, therapies that confer cognitive resilience hold immense value. Hydrogen sulfide’s ability to mitigate vascular and neural insults in this context may redefine therapeutic goals, prioritizing the preservation of cognitive faculties alongside blood pressure control. Such dual-focused treatment paradigms could dramatically improve patient outcomes.
In conclusion, the pioneering study by Kumar and colleagues stands out as a beacon in the endeavor to unravel and counteract hypertension-induced cognitive dysfunction. By elucidating the molecular substrates by which hydrogen sulfide ameliorates endothelial oxidative stress and neuroinflammation, the research opens a new therapeutic frontier. As the science community advances these findings, we may soon witness the integration of gasotransmitter-based interventions in clinical practice, offering hope for millions at risk of cognitive decline associated with hypertension.
Subject of Research:
Article Title:
Article References: Kumar, G., Mishra, S., Goswami, S. et al. Hydrogen sulfide mitigates spatial learning deficits in angiotensin II-Induced hypertension via inhibition of endothelial NOX2 and neuroinflammation. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04178-0
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04178-0
Login